Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov 19;8(11):1463.
doi: 10.3390/cells8111463.

Estrogen Receptors and Melanoma: A Review

Affiliations
Review

Estrogen Receptors and Melanoma: A Review

Emi Dika et al. Cells. .

Abstract

In the last three decades cutaneous melanoma has been widely investigated as a steroid hormone-sensitive cancer. Following this hypothesis, many epidemiological studies have investigated the relationship between estrogens and melanoma. No evidence to date has supported this association due to the great complexity of genetic, external and environmental factors underlying the development of this cancer. Molecular mechanisms through which estrogen and their receptor exert a role in melanoma genesis are still under investigation with new studies increasingly focusing on the discovery of new molecular targets for therapeutic treatments.

Keywords: estrogens; melanoma; woman.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The main estrogen receptors signaling pathways: in the genomic pathway, classic estrogen receptors (ER α and β) act as transcription factors upon homo- or heterodimers. ER α promotes DNA transcription, while ERβ inhibits it. In the non-genomic pathway ERs act as membrane receptors and they lead to increased activity of the RAS/BRAF/MEK axis. Figure 1 demonstrates cross-talk with EGFR receptor pathway. The G protein-coupled estrogen receptor (GPER) acts via intracellular cAMP-protein kinase (PK) and cAMP-response element-binding protein (CREB) phosphorylation.

References

    1. Schadendorf D., van Akkooi A.C.J., Berking C., Griewank K.G., Gutzmer R., Hauschild A., Stang A.A.A., Roesch A.A., Ugurel S. Melanoma. Lancet. 2018;392:971–984. doi: 10.1016/S0140-6736(18)31559-9. - DOI - PubMed
    1. Robsahm T.E., Bergva G., E Hestvik U., Møller B. Sex differences in rising trends of cutaneous malignant melanoma in Norway, 1954–2008. Melanoma Res. 2013;23:70–78. doi: 10.1097/CMR.0b013e32835c7e48. - DOI - PubMed
    1. Weir H.K., Marrett L.D., Cokkinides V., Barnholtz-Sloan J., Patel P., Tai E., Jemal A., Li J., Kim J., Ekwueme D.U. Melanoma in adolescents and young adults (ages 15–39 years): United States, 1999–2006. J. Am. Acad. Derm. 2011;65:S38–S49. doi: 10.1016/j.jaad.2011.04.038. - DOI - PMC - PubMed
    1. Reed K.B., Brewer J.D., Lohse C.M., Bringe K.E., Pruitt C.N., Gibson L.E. Increasing incidence of melanoma among young adults: An epidemiological study in Olmsted County, Minnesota. Mayo Clin. Proc. 2012;87:328–334. doi: 10.1016/j.mayocp.2012.01.010. - DOI - PMC - PubMed
    1. Enninga E.A.L., Moser J.C., Weaver A.L., Markovic S.N., Brewer J.D., Leontovich A.A., Hieken T.J., Shuster L., Kottschade L.A., Olariu A., et al. Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992–2011. Cancer Med. 2017;6:2203–2212. doi: 10.1002/cam4.1152. - DOI - PMC - PubMed